Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Inclusion Criteria: * Had measurable disease according to Standard Diagnostic Criteria at the time of initial Multiple Myeloma diagnosis * Meets criteria for symptomatic multiple myeloma at the time of induction chemotherapy * Is transplant eligible based on clinician judgement * Willing to undergo ASCT in first or second remission * Achieve partial response or better with induction chemotherapy prior to ASCT according to the IMWG Uniform Response Criteria for Multiple Myeloma * Be MRD+ upon restaging prior to stem cell collection and ASCT * Eastern Cooperative Oncology Group (EGOG) performance status score of less than 2 * Life expectancy greater than six months * Have a creatinine clearance \> 45 mL/min/m2 at the time of transplant evaluation * If frozen stem cells from earlier mobilized leukapheresis are unavailable at the time of mobilized leukapheresis, patients must meet parameters/criteria according to institutional SOP for autologous stem cell apheresis * Be willing and clinically stable to undergo stem-cell mobilized and collect enough CD34+ cells sufficient for 2 ASCT per institutional guidelines or investigator discretion or have sufficient frozen cells from a SoC collection prior to signing study consent * Be willing and clinically stable to undergo a non-mobilized MNC-Apheresis while admitted to the hospital to generate CIML NK cells * Be willing to undergo maintenance after ASCT per NCCN guidelines based on disease risk * If a woman of child-bearing potential, be willing to follow birth control and pregnancy testing practice as recommended * Be willing to undergo bone marrow aspirate and biopsy as per treatment plan * Patients must meet adequate organ function/reserve based on institutional SOP for autologous stem cell transplant eligibility * Non-secretory MM can participate if they have measurable disease in the bone marrow and are amenable to be followed by MRD testing Exclusion Criteria: * Prior autologous or allogeneic hematopoietic stem cell transplant * Prior cellular therapies, including NK cell therapy * Prior treatment with monoclonal antibodies, within 28 days of MCN apheresis * Prior treatment with high dose melphalan * Prior treatment with immunosuppressive or immunomodulatory agents with exception of 5 mg or less of prednisone daily, within 14 days of MCN-Apheresis * Disease progression at the time of study treatment * History of Plasma Cell Leukemia at any time prior to enrollment * Patients seropositive for the human immunodeficiency virus (HIV) * Uncontrolled, Hepatitis C Virus or Hepatitis B Virus infection * Patient receiving other investigational therapy * Patients with active, clinically significant autoimmune diseases * Patients with active, clinically significant cancer other than multiple myeloma * Patients with severe, uncontrolled psychiatric or neurological conditions that make difficult the assessment of neurologic toxicity of the study treatment * Patients who have received anti-MM therapy (with the exclusion of monoclonal antibodies) within 14 days of study treatment * More than two prior lines of anti-myeloma therapy, with induction therapy followed by maintenance being considered as one line and CyBorD to RVD transition in the absence of progressive disease being considered as one line